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The development of treatment for patients with non-metastatic
osteosarcoma limb primaries over the past 20 years has led to
impressive improvements in survival with reported long-term
relapse-free survival rates of 55—76% (Link et al, 1990; Bramwell
et al, 1992; Meyers et al, 1992; Bacci et al, 1993). There are,
however, recognized groups of patients who continue to have a
poor outcome. These include patients with unresectable primary
disease; those with metastatic disease at presentation; and those
who relapse either locally or with distant metastases. Long-term
disease-free survival for the first two groups is approximately
0—20% (Schaller et al, 1982; Goorin et al, 1985; Parham et al,
1985; Cassano et al, 1991; Bacci et al, 1992), and 5-year survival
after metastatic relapse has been reported as ranging from 17% to
50% with metastatectomy and/or chemotherapy (Goorin et al,
1984; Huth and Eilber, 1989; Solheim et al, 1992; Tabone et al,
1994; Saeter et al, 1995).
Single-agent and multiagent chemotherapeutic trials have
demonstrated the efficacy of a number of agents in the treatment
of osteosarcoma — including doxorubicin (Cores et al, 1972),
cisplatin (Nitschke et al, 1978), methotrexate (Jaffe et al, 1973)
and ifosfamide (Marti et al, 1985). More recent phase II studies
reveal roles for other agents in combination, most notably etopo-
side (Kung et al, 1985; Grana et al, 1989).
Since 1983, first-line therapy in the UK for children with non-
metastatic limb primaries has been based on cisplatin/doxorubicin
combinations within a series of Medical Research Council trials
(Bramwell et al, 1992; Ornadel et al, 1994). In an attempt to
provide an intensive chemotherapeutic approach for those failing
conventional first line therapy, we have developed a schedule
whereby other active agents, ifosfamide, etoposide and high-dose
methotrexate, could be incorporated in an intensive manner.
Ifosfamide and etoposide combinations have been evaluated previ-
ously in patients with recurrent paediatric sarcomas (Miser et al,
1987; Goorin et al, 1994; Tabone et al, 1994). High-dose
methotrexate has evidence of activity both as a single agent and
within multiple agent trials (Grem et al, 1988; Rosen, 1993). Of
importance, high-dose methotrexate with folinic acid rescue can
be given to neutropenic patients, thereby allowing another agent
to be delivered during the myelosuppressive phase of the
chemotherapy cycle and thus providing a degree of treatment
intensification. This strategy has been successfully used in the
intensification of treatment of non-Hodgkin￿s lymphoma (Muller-
Weihrich et al, 1985).
This report describes the feasibility, toxicity and early response
data of this combination.
METHODS AND PATIENTS
Treatment
The protocol was planned to deliver ifosfamide 2.5 g m—2 over 24 h
with mesna uroprotection at the same dose on 3 consecutive days.
Coincident infusions of etoposide 150 mg m—2 daily for 3 days
were administered over 4 h. High-dose methotrexate (8 g m—2
according to age) was given over 24 h on days 10—14 of a planned
21-day cycle (10% of dose in the first hour and 90% of dose
infused over next 23 h) with appropriate hydration. Folinic acid
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rescue was started 36 h after the start of the methotrexate infusion
at a dose of 15 mg m—2 every 3 h from hour 36 to hour 48, and then
15 mg m—2 6 hourly until the methotrexate level was below 1.0 ´
10—7 M with appropriate adjustments according to methotrexate
level monitoring (minimum ten doses.) Second and subsequent
cycle scheduling were dependent on regain of haematological func-
tion, namely neutrophils > 1.0 ´ 10—9 and platelets > 100 ´ 10—9.
Dose reduction was driven by cytopenia (grade 4) causing major
sepsis or delays to haematological recovery requiring treatment
delay of greater than 1 week.
For clarification of description, one course of ifosfamide/etopo-
side plus one course of high-dose methotrexate constitutes one
cycle of chemotherapy.
Tumour surgery was scheduled on an individual basis when
response to chemotherapy appeared maximal.
Patients
Sequential patients treated with the new combination schedule had
relapsed either with recurrent local disease or distant metastatic
disease. Appropriate local Ethical Committee approval was
acquired in each of the participating centres.
Assessment at entry
Disease assessment at entry included physical examination with
measurements of the diameter of known disease when appropriate.
Imaging studies included plain radiographs of the primary lesion, and
computerized tomography (CT) and/or MRI scans of the primary, in
all those who had not previously had amputation of the primary site.
All had CT scans of the chest and radionuclide bone scans.
Laboratory investigations included evaluation of the full blood
count (FBC), serum electrolytes, urea and creatinine, liver func-
tion tests, calcium, magnesium and phosphate. The glomerular
filtration rate was also assessed using [99mTc] DTPA (diethylene
triamine penta-acetic acid).
Assessment of response
Response of pulmonary metastases was assessed radiologically by
CT scan and/or plain radiographs. Isotope bone scans were also
performed to monitor bone metastases. Assessments were usually
performed after two and six complete cycles. Definitions of
response were as follows: complete response (CR), radiological
disappearance of all evidence of tumour; partial response (PR),
greater than or equal to 50% reduction radiologically in the tumour
diameters at all sites; stable disease (SD), < 25% decrease in size
Table 1 Outcome of treatment with ifosfamide/etoposide alternating with high-dose methotrexate (IEM) related to primary treatment details in relapsed,
evaluable patients
Patient First-line Age at Months Site of Assessment Best No. of Surgery Outcome Max no. Current Survival
no. therapy dx from relapse after two outcome courses at after of status in
relapse primary cycles of IEM best surgery courses months
dx assessment from
relapse
1 Cisplatin/doxorubicin 15 9 Lung SD PR 11 Bilateral CR 11 NED 12
thoracotomies
2 Cisplatin/doxorubicin 14 13 Lung SD CR 10 – – 12 NED 74
3 Cisplatin/doxorubicin 12 19 Lung PR PR 2 Thoracotomy CR 3 DOD 30
4 Cisplatin/doxorubicin 14 10 Lung PR PR 6 Bilateral CR 7 AWD 8
thoracotomies
5 Cisplatin/doxorubicin 15 19 Lung SD SD 4 Bilateral CR 5 NED 8
thoracotomies
6 Cisplatin/doxorubicin 15 16 Lung PR PR 2 Thoracotomy CR 6 NED 8
7 Cisplatin/doxorubicin 10 8 Lung SD SD 4 – – 6 DOD 11
8 Cisplatin/doxorubicin 16 11 Lung PR PR 2 – – 6 DOD 13
9 Cisplatin/doxorubicin 8 6 Lung a PD 3 – – 3 DOD 7
10 Cisplatin/doxorubicin 15 11 Lung, SDa PR 6 Bilateral PR 11 AWD 19
bone thoracotomies
11 Cisplatin/doxorubicin 15 12 Lung, SD PR 6 – – 11 DOD 18
bone,
CNS
12 EOI multidrug 12 26 Bone SD SD 3 Above knee – 3 DOD 8
amputation
13 Cisplatin/doxorubicin 16 11 Local – SD 1.5 – – 2 AWD 9
dx, diagnosis; NED, no evidence of disease radiologically; AWD, alive with disease; DOD, dead of disease. aAssessment after three courses to suit patient
circumstances.
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of one or more lesions; and progressive disease (PD), progression
of one or more of the tumours by greater than or equal to 25% of
the diameter, or appearance of disease at a new site.
Toxicity
Toxicity was assessed using the CTC (common toxicity criteria)
(Franklin et al, 1994), with grade 3 indicating severe and grade 4
indicating unacceptable or life-threatening toxicity (excluding
myelosuppression).
RESULTS
Patient characteristics
Thirteen patients with relapsed osteosarcoma were treated with the
regimen and were evaluable for response. A further two patients
had had tumour surgery at presentation and, consequently, were
additionally evaluable for toxicity assessment.
There were seven males and eight females aged between 6 and
16 years (median 15 years). All fifteen patients had recurrent
disease.
In those patients diagnosed with measurable relapsed disease,
the time interval from initial presentation to diagnosis of recurrent
disease ranged from 6 to 26 months. Lung metastases alone
accounted for disease in nine patients. Three patients had bone
secondaries, one in isolation, one in combination with both CNS
and lung disease and the third patient had a combination of bone
and lung recurrence. One child had a recurrence of his axial
primary disease.
Twelve of these patients had been pretreated on cisplatin/
doxorubicin schedules and one patient had received a multidrug
regimen (methotrexate—vincristine—doxorubicin plus doxoru-
bicin—cisplatin plus bleomycin—cyclophosphamide—dactinomycin)
according to EOI guidelines (Souhami et al, 1997).
Toxicity
There were 98 evaluable cycles, the majority of which were well
tolerated. Myelosuppression of grade 3 or 4 was recorded in 80%
of cycles and febrile neutropenic episodes requiring hospital
admission occurred in 45% of cycles. Only three cycles caused
severe sepsis (grade 4) necessitating subsequent dose reduction.
Three patients required dose reduction of ifosfamide ± etoposide
because of unacceptable haematological toxicity.
Significant renal toxicity was not common. Creatinine levels of
greater than three times normal or a measured glomerular filtration
rate (GFR) of < 40 ml min—1 1.73 m—2 were seen in only four cycles
and were reversible. Renal tubular loss of electrolytes, in particular
magnesium, was common. Magnesium levels of < 0.8 mmol l—1
(normal range 0.65—1.05 mmol l—1) were recorded in 61% of
cycles, but were correctable with oral supplementation. However,
late-onset glomerular dysfunction (Prasad et al, 1996) was beyond
the scope of this study in view of the limited follow-up interval.
Hepatotoxicity was limited to transient elevations of transami-
nases. Mucositis occurred in both the upper and lower GI tract in
some patients, but was generally mild and short lived.
The consequent mean in-patient stay was 11.1 days per cycle
(range 5—27 days). This figure includes both administration of
chemotherapy and inpatient admissions with febrile neutropenic
episodes.
An assessment of the tolerability of the first four cycles of treat-
ment in terms of the ability to proceed on time to subsequent
courses is conveyed by the finding that 13% of the first four cycles
were administered within the prescribed 21 days, 33% within 25
days and 61% were given within 28 days.
Responses
Thirteen patients with relapsed disease were evaluable for
response (Table 1). The response rate after two cycles of
chemotherapy was 31%. Patients with responsive or stable disease
continued on therapy, achieving a best outcome after a further
number of courses and thus giving an overall response rate of 62%
(95% confidence interval 32—86%).
Eight out of 11 patients with pulmonary metastases achieved PR
after 2—10 cycles (patient numbers 1—4, 6, 8, 11, 15). Two patients
remained with stable disease (patients 5 and 7) and one had progres-
sive disease (patient 9). Out of the group with partial response/
stable disease, five were converted to CR with thoracotomy.
In the group with bony metastases, two patients out of three had
a PR after 3—6 cycles. Both of these patients had combined lung
and bone recurrence, PR was essentially judged on the basis of
serial chest CT scans, both patients however demonstrated
concomitant reductions in isotope bone scan activity. One patient
had stable disease after two cycles, but refused further treatment
because of side-effects. One child￿s disease progressed after three
cycles of treatment.
Within the group of patients with relapsed disease, four patients
are alive with no evidence of disease 8—74 months after entry into
the study. Three patients are alive with radiological evidence of
disease 8—19 months later. Six patients have died from their
disease 7—30 months later. There were no toxic deaths.
Figure 1 details Kaplan—Meier analyses of overall survival from
commencement of the chemotherapy regimen in evaluable
patients. The median survival time was 18 months from
commencement of the regimen, with 95% confidence intervals
ranging from 0 to 54 months.
DISCUSSION
The outlook for children and young adults with recurrence of
osteosarcoma or primary metastatic disease remains poor. When
the lung is the only site of disease recurrence, a surgical approach
in which all resectable deposits are removed has been advocated as
potentially curative, with a reported 5-year survival rate from first
thoracotomy of 23—50% (Schaller et al, 1982; Meyer et al, 1987;
Belli et al, 1989; Snyder et al, 1991; Skinner et al, 1992; Ward et
al, 1994; Saeter et al, 1995; Han et al, 1996). Development of bony
metastases carries a worse prognosis with a 0% 4-year survival
rate (Ward et al, 1994).
The place of chemotherapy in the management of recurrent or
advanced osteosarcoma is not of proven benefit, especially in
those already heavily pretreated (Han et al, 1981; Meyer et al,
1987; Cassano et al, 1991). However, a number of regimens have
been reported to have been used in this situation (Morgan et al,
1984; Solheim et al, 1992; Ward et al, 1994); including ifosfamide
and etoposide in combination (Miser et al, 1987; Goorin et al,
1994; Tabone et al, 1994; Gentet et al, 1997).
Ifosfamide is considered by some authors to be one of the most
effective treatments in osteosarcoma, with response rates recorded
in the region of 67% (Chawla et al, 1990). Other phase II studiesconfirm its efficacy as a single agent and in combination schedules
(Marti et al, 1985; Harris et al, 1995). Etoposide has been used in a
number of phase II trials in children with recurrent malignant solid
tumours, and has shown a high proportion of complete and partial
responses (Chard, 1979; O￿Dwyer et al, 1985); however, single-
agent usage in osteosarcoma has been disappointing. Support for
its efficacy in combination with ifosfamide is provided by the
results of the Rizzoli institute￿s second neoadjuvant study in which
it was used as salvage therapy (Bacci et al, 1993), and the results of
the Children￿s Cancer Group (Miser et al, 1987). The tolerability
of this combination is aided by the fact that their non-haemopoi-
otic toxicities do not overlap.
There is a considerable body of evidence supporting the role of
high-dose methotrexate in the treatment of osteosarcoma since its
first use in the 1970s, both as a single agent and as part of multi-
agent trials (Grem et al, 1988; Rosen, 1993). The advantages of
adding high-dose methotrexate to an ifosfamide/etoposide combi-
nation include that, individually, it has an impressive single-agent
profile; myelotoxic schedules can be resumed after only 1 week of
administering HDMTX; and, properly administered, there is
minimal toxicity. In addition, especially latterly, current MRC
protocols for first-line treatment of osteosarcoma do not include
high-dose methotrexate and therefore relapsing patients have not
had prior experience of this drug.
The toxicity profile overall was tolerable. There was no treat-
ment-related mortality. The renal tubular electrolyte loss related to
ifosfamide chemotherapy required close monitoring and oral
supplementation, but no patient required dose reduction because of
renal complications. Haematological toxicity resulted in febrile
neutropenia events that required inpatient stay and occasional
dose-reduction consequently. But the majority of courses were
well tolerated.
The results of this retrospective analysis suggest an encouraging
response rate of 62%, in a group of children with poor prognosis
disease. We have observed a delayed response rate to this regimen
in patients who had stable disease at reassessment after two cycles.
Patients with SD had radiological PR or CR by 6—10 cycles, indi-
cating that classic phase 2 methodology of assessment after two
cycles may not always be adequate. The number of patients evalu-
ated are obviously too few to be considered statistically significant
and the period of follow-up is limited. However, the regimen
deserves consideration for an appropriate multi-institutional
evaluation.
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